Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
REPL
Replimune Group, Inc.
Engineered viral vectors delivering therapeutic payloads resemble gene therapy approaches.
|
$549.51M |
$7.03
-3.77%
|
|
STKL
SunOpta Inc.
The company functions as a co-manufacturer and private label partner, providing manufacturing services to brands and retailers.
|
$548.97M |
$4.64
-0.43%
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$548.49M |
$10.13
-2.36%
|
|
PRME
Prime Medicine, Inc.
Directly develops gene editing therapeutics (Prime Editing) and the core therapeutic platform, i.e., gene therapy.
|
$535.60M |
$3.98
-0.25%
|
|
DSGN
Design Therapeutics, Inc.
Company develops small-molecule therapeutics (GeneTAC) targeting inherited nucleotide repeat disorders.
|
$528.48M |
$9.27
-0.96%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is an oncology-focused therapeutic developed by SELLAS, targeting cancer antigens (WT1) and used as an immunotherapy.
|
$526.49M |
$4.09
-18.10%
|
|
LENZ
LENZ Therapeutics, Inc.
VIZZ is an aceclidine-based eye drop marketed as an ophthalmic drug for presbyopia.
|
$521.67M |
$18.27
+0.74%
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$515.37M |
$4.67
-6.87%
|
|
CRMD
CorMedix Inc.
Melinta acquisition adds a diversified antibiotic portfolio expanding revenue mix into infectious disease therapeutics.
|
$506.12M |
$6.77
-3.42%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$503.31M |
$9.36
+1.03%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon's pipeline includes oral small-molecule therapeutics pilavapadin (LX9211) and LX9851; these are oral small-molecule drugs, a major product category in their portfolio.
|
$497.86M |
$1.38
+7.42%
|
|
OCGN
Ocugen, Inc.
Ocugen's modifier gene therapy platform and lead retinal candidates (OCU400/OCU410) are gene therapy products targeting vision disorders.
|
$494.00M |
$1.69
+4.32%
|
|
ORGO
Organogenesis Holdings Inc.
ReNu knee osteoarthritis program is a cell therapy (biotech) product, aligning with Biotech - Cell Therapy.
|
$480.79M |
$3.79
-4.53%
|
|
ENGN
enGene Holdings Inc.
engGene's core platform is non-viral gene therapy delivery (DDX platform) and its lead asset is a gene therapy product, placing it squarely in Gene Therapy.
|
$476.60M |
$9.34
+1.30%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's core product is TPOXX, a small-molecule antiviral for orthopoxviruses, directly produced and marketed by the company.
|
$471.17M |
$6.58
-0.53%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$469.82M |
$8.18
-0.49%
|
|
ZVRA
Zevra Therapeutics, Inc.
Zevra focuses on rare-disease therapeutics (NPC, UCD, VEDS) and related pipeline assets, core to rare disease biotech.
|
$466.48M |
$8.48
+2.05%
|
|
ANRO
Alto Neuroscience, Inc.
Company focuses on Neuropsychiatric drug development across MDD, bipolar depression, TRD, and schizophrenia using precision psychiatry.
|
$464.91M |
$17.21
+1.12%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$459.99M |
$19.23
+0.29%
|
|
LYEL
Lyell Immunopharma, Inc.
Lyell’s lead program LYL314 is a CAR-T cell therapy product targeting cancer (CD19/CD20 dual-target), the core business.
|
$456.46M |
$23.95
+4.47%
|
|
BCYC
Bicycle Therapeutics plc
Company's core focus is oncology with Bicycle Molecule platform and multiple lead oncology programs.
|
$451.19M |
$6.53
+0.93%
|
|
NWBO
Northwest Biotherapeutics, Inc.
NWBO is a cancer-focused biotechnology company developing oncology immunotherapies (DCVax) and related products; tags align with Biotech - Oncology.
|
$444.63M |
$0.30
|
|
VNDA
Vanda Pharmaceuticals Inc.
Fanapt and other marketed/potential small-molecule therapies (e.g., Tradipitant) are oral small molecule therapeutics.
|
$441.40M |
$7.47
+0.34%
|
|
AVXL
Anavex Life Sciences Corp.
Company's lead product and pipeline consist of oral small-molecule therapeutics (ANAVEX 2-73 and ANAVEX 3-71).
|
$430.33M |
$5.01
+3.40%
|
|
IMMP
Immutep Limited
Immutep is focused on immunology therapeutics, including LAG-3 modulation for cancer and autoimmune diseases.
|
$427.94M |
$2.94
-3.14%
|
|
SLDB
Solid Biosciences Inc.
Solid Biosciences is developing viral-vector gene therapies (SGT-3.00, SGT-212, SGT-501) and related products, fitting squarely under Biotech - Gene Therapy.
|
$425.94M |
$5.49
-3.00%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$418.41M |
$11.00
+1.66%
|
|
CLPT
ClearPoint Neuro, Inc.
SmartFlow cannula represents a drug-delivery platform for targeted brain infusion, tied to cell/gene therapy delivery approaches.
|
$416.46M |
$14.65
+0.03%
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$415.13M |
$33.54
+2.60%
|
|
CYBN
Cybin Inc.
Company's pipeline focuses on neuropsychiatric drug development (MDD, GAD) with CYB003/CYB004.
|
$413.12M |
$8.30
+1.53%
|
Showing page 11 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
